论文部分内容阅读
目的：建立联合诊断恶性肿瘤的血清学指标，提高诊断的准确性。方法：应用快速微粒子捕捉双抗夹心酶免疫分析法测定实验组182例手术前后血清中的癌胚抗原（CEA）、癌相关糖抗原CA19-9、CA12-5、CA15-3，并与62例健康对照组比较。结果：在6种恶性肿瘤中，除卵巢癌外，肿瘤标志CEA在其它恶性肿瘤均显著升高（P＜0．001），除乳腺癌、肺癌外，肿瘤标志CA19-9在其它恶性肿瘤均显著升高（P＜0．001），CA12-5在胰腺癌、卵巢癌中显著升高（P＜0.001），CA15-3在乳腺癌、肺癌中显著升高（P＜0.001）。结论：同时选择几种特异性较高的血清肿瘤标志，进行联合测定，可提高肿瘤临床诊断的阳性率。
Objective: To establish a joint diagnosis of malignant serological markers and improve the accuracy of diagnosis. METHODS: The serum anti-carcinoembryonic antigen (CEA), cancer-associated carbohydrate antigens CA19-9, CA12-5, and CA15-3 in 182 cases of the experimental group were determined by rapid microparticle capture double-antibody sandwich enzyme immunoassay and compared with 62 cases. Comparison of healthy control groups. Results: In 6 malignant tumors, except for ovarian cancer, the tumor marker CEA was significantly higher in other malignant tumors (P<0.001). In addition to breast and lung cancer, the tumor marker CA19-9 was found in other malignant tumors. Significantly increased (P<0.001), CA12-5 was significantly higher in pancreatic and ovarian cancers (P<0.001), and CA15-3 was significantly higher in breast and lung cancers (P<0.001). Conclusion: Selecting several serum tumor markers with higher specificity at the same time for combined determination can increase the positive rate of clinical diagnosis.